Prenuvo Raises $120M, Adds New Health Screens

Prenuvo is bringing the whole body into focus.

What’s happening: The preventative scan clinic closed a $120M Series B co-led by Left Lane Capital, Forerunner Ventures, and Felicis.

Expanding beyond full-body MRIs, Prenuvo announced new screenings, including a proprietary brain scan, body composition analysis, and labs for hormonal, heart, and immune health.

No wait. Debated in the medical community, Prenuvo is winning over consumers — to date, it has delivered 1.4M personalized insights to 110K members at 17 North American clinics.

Notching $100M in revenue last year, the company has solid footing for expansion, planning 15 clinics in the coming months, including in Europe and Australia.

Head to toe. Bundling its new services, patients will pay $4K out of pocket — $1.5K more than its signature AI-powered MRI scan used to check for cancers, aneurysms, and more.

Extending its purview to more conditions, Prenuvo will deliver an FDA-cleared body comp report, early warning for cardiac and neurodegenerative diseases, and blood-derived insights into areas like women’s and metabolic health.

Checking in. AI is revolutionizing healthcare, and for overburdened wellness seekers, its ability to quickly deliver peace of mind is priceless.

Coming with answers, scan clinics Neko Health, Ezra, and Q Bio are scaling fast, while AI software from Sweden’s Corsmed cut traditional MRI times from 45 minutes to two.

Looking ahead: While overimaging runs its own risks for providers and patients, catching conditions otherwise left unchecked may outweigh the detriments.